Author response: Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham study.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. New insight into Alzheimer's disease: small molecule-Aβ in the brain transport and peripheral organ clearance.Frontiers in aging · 2026
   Review
2. Cognitive impairment and liver fibrosis in non-alcoholic fatty liver disease.BMJ neurology open · 2024
   Article
3. Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults.Clinical and molecular hepatology · 2022
   Article
4. Association of serum brain-derived neurotrophic factor with hepatic enzymes, AST/ALT ratio, and FIB-4 index in middle-aged and older women.PloS one · 2022
   Article

Corrections and comments

• Comment on
  Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study.2019
• Comment on
  Cognitive impairment in patients with nonalcoholic fatty liver disease with liver fibrosis.2020

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as